An experimental therapy has brought prolonged remissions to a high proportion of patients who were facing death from advanced leukemia after standard treatments had failed, researchers are reporting.
The therapy involves genetically programming cells from the patient’s own immune system to fight the disease.
The research included 30 patients: five adults ages 26 to 60, and 25 children and young adults ages 5 to 22. All were severely ill, with acute lymphoblastic leukemia, and had relapsed several times or had never responded to typical therapies. In more than half, the disease had come back even after a stem-cell transplant, which usually gives patients the best hope of surviving. Their life expectancy was a few months, or in some cases just weeks.
Six months after being treated, 23 of the 30 patients were still alive, and 19 of them have remained in complete remission.
“We have a number of patients who are a year or more out and are in remission and not requiring other therapies,” said Dr. Stephan A. Grupp, who led the part of the study done at Children’s Hospital of Philadelphia. He said those long remissions gave the researchers hope that the treatment would have lasting effects.
Earlier reports by the same researchers involved only a handful of patients, some with chronic rather than acute leukemia. The scientists say the growing number of patients treated helps demonstrate that the findings are real.
The Latest on: Leukemia
via Google News
The Latest on: Leukemia
- Repurposing anthelmintic agents to eradicate resistant leukemiaon June 26, 2020 at 9:39 am
Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific ...
- Global Chronic Myeloid Leukemia Industry Study 2020 - Develop In-depth Knowledge of Competition and Markets - ResearchAndMarkets.comon June 26, 2020 at 9:09 am
The "Global Chronic Myeloid Leukemia Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights into the Chronic ...
- Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market Overview, Industry Trends and Growing Opportunities Till 2026on June 26, 2020 at 4:13 am
A recent report provides crucial insights along with application based and forecast information in the Global Acute Lymphocytic/Lymphoblastic Leukemia Drugs Market. The report provides a comprehensive ...
- Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market 2020 Analysis Research and Development Forecast by 2026on June 26, 2020 at 4:08 am
Jun 26, 2020 (Profound via COMTEX) -- A recent report provides crucial insights along with application based and forecast information in the Global Acute Lymphocytic/Lymphoblastic Leukemia ...
- Research team solves 40-year old mystery in leukemia treatmenton June 25, 2020 at 8:54 am
University Frankfurt am Main, has solved an almost 40-year old mystery in leukemia therapy and the drug nelarabine.
- Acute Lymphoblastic Leukemia Market is Expected to Grow with 4.8% CAGR During the Study Period of 2017-30 in 7 Major Marketson June 25, 2020 at 7:00 am
DelveInsight has announced the expansion of the forecast period to 2020-2030 for its report on 'Acute Lymphoblastic Leukemia (ALL) ...
- Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemiaon June 25, 2020 at 2:29 am
The FDA-approved DNA hypomethylating agents (DHAs) like 5-azacytidine (5AC) and decitabine (DAC) demonstrate efficacy in the treatment of hematologic malignancies. Despite previous reports that showed ...
- Texans’ Lonnie Johnson Jr. delivers message to young leukemia survivor: ‘He can inspire you’on June 24, 2020 at 5:35 pm
A young leukemia survivor has made a huge impression on Texans cornerback Lonnie Johnson Jr., inspiring the second-year NFL player to deliver a video message of hope and encouragement.
- Oncotarget: RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferationon June 23, 2020 at 9:03 am
BI-D1870 treatment increased the G2/M population and induced apoptosis in Acute Myeloid Leukemia cell lines and patient Acute Myeloid Leukemia cells. Therefore, the authors investigated whether ...
- Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029on June 22, 2020 at 5:00 am
Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by abnormal proliferation or differentiation of myeloid progenitors in the bone marrow ...
via Bing News